DENVER, Colo. (247marketnews.com) -- bioAffinity Technologies (NASDAQ:BIAF) has just added a potentially significant commercial channel for CyPath Lung, announcing a nationwide federal healthcare distribution agreement with AvMEDICAL, a Service-Disabled Veteran-Owned Small Business with established government procurement relationships.
The agreement gives AvMEDICAL’s national sales organization a mandate to market CyPath Lung to federal healthcare agencies, including VA medical centers nationwide. For bioAffinity, the significance goes beyond simply adding another distributor: the partnership puts the company’s noninvasive lung-cancer diagnostic directly into a government healthcare supply chain that already serves a population with a substantial lung-cancer burden.
Maria Zannes, President and CEO of bioAffinity Technologies, stated, “AvMEDICAL’s established presence in the government healthcare marketplace and experienced sales organization will expand our commercial pathway.” She pointed specifically to the VA’s roughly 8,000 annual veteran lung-cancer diagnoses and approximately 5,000 annual deaths. VA itself has reported similar figures and identifies lung cancer as its deadliest cancer.
The timing is notable because bioAffinity has already been reporting accelerating commercial activity. The company said CyPath Lung test volume increased 216% year over year in the second quarter of 2026, suggesting that the commercial story is beginning to move beyond clinical validation toward actual utilization.
CyPath Lung is designed to provide additional information when physicians evaluate indeterminate pulmonary nodules. It uses sputum, flow cytometry and a proprietary AI-based analysis to categorize patients according to lung-cancer risk. In a published clinical study involving high-risk patients with small indeterminate nodules, the company reported 92% sensitivity, 87% specificity, 88% accuracy and 99% negative predictive value. The test is marketed as a Laboratory Developed Test and is intended to be used alongside other clinical information, not as a standalone diagnostic.
That could make the VA an especially interesting proving ground for CyPath Lung. VA has been aggressively expanding lung-cancer screening, with nearly 8,000 veterans diagnosed and treated for lung cancer annually and more than 900,000 veterans previously identified as potentially eligible for screening.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.